Strides Pharma's Chestnut Ridge Facility Secures USFDA VAI Closure

Strides Pharma Science Ltd's (

) US subsidiary, Strides Pharma Inc., received a Voluntary Action Indicated (VAI) classification from the US Food and Drug Administration (USFDA) for its Chestnut Ridge, New York facility, following an inspection from December 17 to 23, 2025. This outcome, based on the company's response to the Form 483 observations, resulted in the issuance of an Establishment Inspection Report (EIR) confirming closure, with no mandatory actions required. The inspection evaluated current good manufacturing practices and pre-approval processes for drug-device combinations, including nasal spray filings. The facility produces US-market liquids, gels, hormones, modified-release products, and controlled substances, bolstering Strides' product pipeline. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.